China has the highest incidence of gastroesophageal cancer globally, and therapeutic options are limited. Only five targeted agents are approved for treatment—trastuzumab (Roche’s Herceptin,…
Breast cancer is the most commonly diagnosed cancer in women in China. The disease has been managed primarily through chemotherapy in China, but several novel, premium-priced targeted therapies—…
Bladder cancer is the eighth most commonly diagnosed cancer in China. The bladder cancer therapy market is set to enter a competitive and dynamic period of rapid growth, fueled by one of the most…
Chemotherapy and hormonal therapy have been the mainstay treatments of advanced endometrial carcinoma, but treatment is becoming more directed, as a result of tumor analysis. Immune checkpoint…
Bladder cancer is the eighth most commonly diagnosed cancer in China. The bladder cancer therapy market is set to enter a competitive and dynamic period of rapid growth, fueled by one of the most…
Hormonal agents are the mainstay treatment for prostate cancer and are routinely used in all lines of therapy, even as novel agents like Orgovyx (Myovant) enter the treatment algorithm. Zytiga (…
Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related deaths in China—has a highly dynamic drug development pipeline, including several targeted and biomarker-driven therapies…
A crowded generics market makes gaining a strong foothold in the treatment of chronic pain challenging for branded agents. The treatment of chronic pain involves the use of drugs from several drug…
The incidence of gastroesophageal cancer—encompassing gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ) adenocarcinoma—continues to rise; however, treatment options remain…
The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy was the standard of care, but with the introduction of Roche / Genentech / Chugai’s angiogenesis inhibitor…
Biomarker-driven prescribing is paramount in key oncology indications. Biomarkers play an important role and are well-entrenched in indications such as non-small-cell lung cancer and malignant…
NASH has the potential to be a large and lucrative therapy market owing to the disease’s prevalence and the lack of approved agents. Patients with NASH are at risk of liver fibrosis,…
The 2016 and 2017 FDA approvals of multiple immune checkpoint inhibitors for advanced bladder cancer have greatly altered the treatment landscape for this disease. The FDA’s (2020) and EC’s (…
UNDERSTAND THE TOTAL MARKET SIZE AND TREATMENT OPPORTUNITIES FOR BIOMARKERS The development of biomarker-driven therapies continues to be a major trend in oncology. As biomarkers are often…
DRG Epidemiology's coverage of venous thromboembolism prophylaxis in cancer comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the…